What’s new so early in the new year? Read on…
As many of you who follow this blog know, pCODR is the new pan-Canadian Oncology Drug Review Process. pCODR’s role is to evaluate all new oncology drugs specifically to determine whether they should be reimbursed by our provincial drug plans (excepting Quebec).
This past week pCODR issued its latest recommendation for the latest kidney cancer drug, axitinib (or Inlyta). For those of you interested in how this process works, I invite you to read the full recommendation here on pcodr.ca
This recommendation is open for feedback until Monday January 28th. As a registered patient advocacy group, Kidney Cancer Canada will be responding with several concerns:
1. That the condition of “intolerant to Afinitor/everolimus” is not evidence-based nor does it work in the best interests of patient CHOICE and ACCESS to the most appropriate treatment for that patient.
Note: We saw this same condition placed on Votrient / pazopanib a year ago and have since watched delay after delay as each province grappled with the “intolerant to Sutent” condition. In many provinces, patients and their oncologists have to jump through unnecessary hoops before they can access Votrient.
2. That the lack of direct drug-to-drug trials is being held as an unreasonable standard or request for a rare cancer such as kidney cancer. It is not reasonable to expect industry to conduct direct head-to-head trials for every possible comparison or sequence — especially for a rare cancer, and especially not at a time when new agents are coming out every year. So yes, there will always be some uncertainty of which of two drugs works best overall, but in rarer cancers, we all have to live with those uncertainties. We cannot stop patients from accessing newer treatments just because there is no Level 1 evidence (large, phase 3 studies) that take years to report.
If you’re interested in the kind of work we do behind the scenes for treatment advocacy, please follow this link to our public folder for pCODR submissions. Our position is that we want ALL Canadians to have access to ALL treatments for kidney cancer that have been approved by Health Canada. We work on each and every drug submission, survey our membership and do our best to represent your voices with pCODR and with our provincial governments.
So, the next time someone asks you what Kidney Cancer Canada does to support patients in Canada, please remember this note. We are planning to burn the midnight oil between now and Monday Jan 28th to make sure we respond appropriately.
If this matters to you, please do let us know. And if you can find a way to support our work as volunteers, please do consider a donation to help with all of the things we’re NOT doing while we’re tied up dealing with pCODR.
Thank you for listening!
Deb & the KCC Advocacy Working Group